Psilocybin patents

US US3192111A Hofmann Albert Sandoz Ltd

Priority 1959-02-16 • Filing 1962-05-14 • Grant 1965-06-29 • Publication 1965-06-29

2. THE METHOD OF INDUCING THERAPEUTIC TRANQUILIZATION, WHICH COMPRISES ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF CRYSTALLINE PSILOCYBIN.

US CH ES LU US3183172A Heim Roger Sandoz Ltd

Priority 1958-02-21 • Filing 1959-02-16 • Grant 1965-05-11 • Publication 1965-05-11

1. A process for obtaining the psychotropically active compounds psilocybin and psilocin, which comprises extracting the active principles from fungal material of one of the species Psilocybe mexicana Heim, Stropharia cubensis Earle, Ps locybe semperviva Heim and Cailleux, Psilocybe caerulescens …

AT AT211955B Sandoz Ag

Priority 1958-07-30 • Filing 1959-02-13 • Grant 1960-11-25 • Publication 1960-11-25

<Desc / CLMS Page number 1> A process for obtaining the novel compounds Psilocybin and psilocin The present invention relates to a method for obtaining the previously unknown, psychotropic active compounds psilocybin and psilocin from fungal species. It was already known (R. Heim, C. r. Hebd.

WO NL NL2018190B1 Küçüksen Murat Procare Beheer B V

Priority 2017-01-18 • Filing 2017-01-18 • Grant 2018-07-26 • Publication 2018-07-26

6. psilocybin and / or psilocin in combination with at least one cannabinoid for use according to any one of the preceding claims, wherein the at least one cannabinoid is present in a pure form. 7. psilocybin and / or psilocin in combination with at least one cannabinoid for use according to any …

WO US GB US20190119310A1 Derek John Londesbrough Compass Pathways Limited

Priority 2017-10-09 • Filing 2018-10-09 • Publication 2019-04-25

FIG. 8 a or 8 b. 2 . Crystalline psilocybin in the form Polymorph A or Polymorph A′, according to claim 1 further characterised by an endothermic event in a DSC thermogram having an onset temperature of between 210 and 215° C. 3 . Crystalline psilocybin in the form Polymorph A, according to claim 1

GB GB911946A Sandoz Ltd

Priority 1958-02-21 • Filing 1959-02-11 • Publication 1962-12-05

The invention comprises the psychotropically active compounds Psilocybin of the formula: <FORM:0911946/IV (b)/1> and Psilocin of the formula: <FORM:0911946/IV (b)/2> and a process for their extraction from fungal material of the genera Psilocybe, Stropharia and Panaeolus or biological variants or …

CH CH377482A Hofmann Albert Sandoz Ag

Priority 1958-07-30 • Filing 1958-07-30 • Publication 1964-05-15

A process for recovering psilocybin and psilocin according to claim, characterized in that one uses as starting material the hat mushroom Psilocybe the genus, species Zapotecorum home ver. 5. A process for obtaining psilocybin and psilocin according to claim, characterized in that as starting …

WO US US20180221396A1 Andrew R. Chadeayne CaaMTech, LLC

Priority 2017-02-09 • Filing 2018-02-09 • Publication 2018-08-09

, comprising a molar ratio between about 10:1 to about 1:10 of the first purified psilocybin derivative to the second purified psilocybin derivative. 3 . The composition of claim 1 , comprising a molar ratio between about 100:1 to about 1:100 of the first purified psilocybin derivative to the second …

CS CS276073B6 Marta Rndr Csc Semerdzieva Mikrobiologicky Ustav Csav

Priority 1990-08-14 • Filing 1990-08-14 • Publication 1992-03-18

EE preparation solves paychotropnlch substances peilocybinu peilociau and culturing the fungi Psilocybe bohemiea Šebek whose mycelium produces deep culturing conditions and on a liquid complex medium substantially higher concentrations of these substances. The purpose is to allow the fermentative …

US US20190105313A1 Paul Edward Stamets Paul Edward Stamets

Priority 2016-07-23 • Filing 2018-12-06 • Publication 2019-04-11

1 . A composition comprising: psilocybin, psilocin, baeocystin, norbaeocystin, or salts thereof, psilocybin mushrooms or extracts thereof, or combinations thereof; and niacin. 2 . The composition of claim 1 , wherein the composition further comprises Bacopa species ( Bacopa monnieri ), Gotu kola ( …

WO2019099745A1 Andrew CHEDEAYNE CaaMTech, LLC

Priority 2017-11-16 • Filing 2018-11-15 • Publication 2019-05-23

13. The composition of claim 11, wherein the first cannabinoid is chosen from THC, THC A, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV, or CBGVA. 14. The composition of claim 11, wherein the first psilocybin derivative is a purified psilocybin derivative. 15. The …

US US20190142851A1 Andrew R. Chadeayne CaaMTech, LLC

Priority 2017-11-16 • Filing 2018-11-15 • Publication 2019-05-16

wherein the first psilocybin derivative and the first purified cannabinoid are present as a homogeneous mixture within the composition. 11 . A composition comprising a first psilocybin derivative and a first cannabinoid. 12 . The composition of claim 11 , wherein the first psilocybin derivative is …

DK DK98374C Sandoz Ag

Priority 1958-02-21 • Filing 1959-01-28 • Grant 1964-04-06 • Publication 1964-04-06

IE IE24138L Sandoz Ag

Priority 1959-02-18 • Filing 1959-02-18 • Publication 1959-08-21

DE DE1087321B Roger Heim Sandoz Ag

Priority 1958-02-21 • Filing 1959-01-31 • Publication 1960-08-18

CA CA672478A Heim Roger Heim Roger

Grant 1963-10-15 • Publication 1963-10-15

FR NL FR1298308A Sandoz Sa

Priority 1958-02-21 • Filing 1959-02-19 • Grant 1962-07-13 • Publication 1962-07-13

DK DK98552C Sandoz Ag

Priority 1958-02-21 • Filing 1959-01-28 • Grant 1964-04-27 • Publication 1964-04-27

WO EP US AU CA DK EA ES PL US20150335689A1 Paul Edward Stamets Paul Edward Stamets

Priority 2000-10-04 • Filing 2015-03-08 • Publication 2015-11-26

The present invention is based on a plurality of benefits from the extracts of mycelia of individual fungal species, and mixtures of species, to provide an armamentarium of defenses from multiple stressors in order to help bees survive a complex of symptoms collectively called colony collapse …

WO US AU CA US20050176583A1 Paul Stamets Stamets Paul E.

Priority 2001-02-20 • Filing 2003-07-07 • Publication 2005-08-11

The present invention utilizes fungal spore mass or hyphal fragments in landscaping cloths, fiber substrates, paper products, hydroseeders and agricultural equipment. The fungi may include saprophytic fungi, including gourmet and medicinal mushrooms, mycorrhizal fungi, entomopathogenic fungi, …

WO EP US JP CA ES US10064856B2 Paul Bosse Local Pharma, Inc.

Priority 2008-01-09 • Filing 2017-08-22 • Grant 2018-09-04 • Publication 2018-09-04

Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

WO EP US CN JP KR AU CA RU JP6343147B2 ドナルド イー． イングバー プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ

Priority 2010-08-30 • Filing 2011-08-30 • Grant 2018-06-13 • Publication 2018-06-13

… , methoxamine, methylphenidate, metizoline, metaraminol, midodrine, naphazoline, nordefrin, norepinephrine, octodrine, ornipressin, oxymethazoline, phenyl ethanolamine, phenylephrine, phenylpropanolamine isopropylamine, phenylpropanolamine, Fe Pressin, propylhexedrine, pseudoephedrine, psilocybin, …

US US20030224435A1 Scott Seiwert Scott Seiwert

Priority 2002-05-16 • Filing 2003-05-16 • Publication 2003-12-04

… , LSD (Lysergic acid diethylamide), Mannitol, Marijuana (THC), Mescaline, Methadone, Methamphetamine, Methaqualone, Methcathinone, Methylphenidate (ritalin), Morphine, Nexus (2CB), Nicotine, Opium, Oxycodone, OxyContin, PCP (phencyclidine), Peyote, Phenobarbital, Procaine, Psilocybin, Psilocybin/ …

WO EP US JP AU CA US20020128250A1 Robert Busby Robert Busby

Priority 1999-10-20 • Filing 2001-03-07 • Publication 2002-09-12

The invention relates to the production of secondary metabolites by fungi. More particularly, the invention relates to improvement of production of commercially important secondary metabolites by fungi. The invention provides methods for improving secondary metabolite production in a fungus, …

WO US AU US20040180147A1 Atul Parikh The Regents Of The University Of California

Priority 2002-10-30 • Filing 2003-10-30 • Publication 2004-09-16

This invention provides novel methods for creation of patterned lipid bilayer membranes as well as methods for refunctionalization of such patterned membranes with selected components. Such components optionally comprise, e.g., lipid bilayer membranes (which optionally comprise specific proteins), …

WO EP US CN JP KR AU BR CA IN US9549886B2 Dorie J. Yontz Gfbiochemicals Limited

Priority 2010-05-10 • Filing 2014-11-07 • Grant 2017-01-24 • Publication 2017-01-24

Personal care formulations containing alkyl ketal esters having the structure wherein a is 0 or an integer of 1 to 12; b is 0 or 1; R 2 is a divalent C 1-8 group optionally substituted with up to 5 hydroxyl groups; and R 1 is C 1-6 alkyl.

WO EP US CN JP KR AU BR CA MX PH TW CN108712918A P.达维德森 塞基医疗有限公司

Priority 2016-01-11 • Filing 2017-01-11 • Publication 2018-10-26

According to some embodiments there is provided a device configured for releasing at least one substance from a source material, comprising: a housing; a plurality of source material sections positioned at fixed locations with respect to the housing; a plurality of airflow paths, each airflow path …

WO EP US CN JP AT AU CA CY DE DK ES HK US20030099668A1 Martin Bachmann Cytos Biotechnology Ag

Priority 2001-09-14 • Filing 2002-09-16 • Publication 2003-05-29

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce …

WO EP US JP AU CA US20030091593A1 Martin Bachmann Cytos Biotechnology Ag

Priority 2001-09-14 • Filing 2002-09-16 • Publication 2003-05-15

The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant …

WO EP US CN JP KR AU BR CA IL IN MX NZ PL RU ZA EP2392345A2 Martin F. Bachmann Cytos Biotechnology AG

Priority 2002-07-18 • Filing 2003-07-18 • Publication 2011-12-07

The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention comprise drugs, especially drugs of addiction such as nicotine. Compositions …

WO EP US US10245323B2 Randice Lisa Altschul Pop Test Abuse Deterrent Technology Llc

Priority 2014-06-03 • Filing 2018-05-23 • Grant 2019-04-02 • Publication 2019-04-02

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

WO EP US CN JP AU BR CA CO ES MX NZ PH RU SG CA2695372C Tom Woiwode Synosia Therapeutics, Inc.

Priority 2007-08-06 • Filing 2008-08-06 • Grant 2013-01-22 • Publication 2013-01-22

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in …

WO EP US CN US20110086063A1 Ronald G. Crystal Cornell University

Priority 2008-06-04 • Filing 2009-06-04 • Publication 2011-04-14

The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody …

US US9551695B2 Dalita Tomellini Lindon Group, Inc.

Priority 2012-01-24 • Filing 2013-01-23 • Grant 2017-01-24 • Publication 2017-01-24

A personal-sized, portable explosive detection field test kit (ETK) and related methods of use. Embodiments of the disclosed ETK include a case having a closing system featuring three levels of closure which retain the case cover securely in a closed position until ready for use, while being …

JP JP4174016B2 博史 北條 株式会社ビーエル

Priority 2003-07-11 • Filing 2003-07-11 • Grant 2008-10-29 • Publication 2008-10-29

(Detection of psilocin and psilocybin in the test sample) Providing a magic mushrooms containing psilocin and psilocybin as a test sample, Bunashimeji not containing any of psilocin and psilocin as a control sample, shiitake was prepared Maitake and eryngii. Each of the test and control samples, …

DD DD264023A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1987-07-17 • Filing 1987-07-17 • Publication 1989-01-18

The invention relates to a process for recovering the indole alkaloids psilocybin, psilocin baeocystin and by extraction of the mycelia and fruiting bodies of higher fungi. The active ingredients are applicable as model substances in neurobiological research. The alkaloids are transferred from the …

WO EP US CN JP KR AU CA IL MX RU KR20170026520A 페리 데이비드손 사이키 메디컬 엘티디.

Priority 2014-06-30 • Filing 2015-06-30 • Publication 2017-03-08

To a subject an amount of one or more drugs of the active agent vaporize one or more predetermined in the plant material there is provided a system comprising a metered dose inhaler device for pulmonary delivery, vaporized in order to vaporize the vaporizing amount predetermined in the …

DD DD254395A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1986-12-08 • Filing 1986-12-08 • Publication 1988-02-24

The invention relates to a process for the recovery of the active ingredients psilocybin and psilocin by culturing the fruiting bodies of higher fungi. The active ingredients are applicable as model substances in neurobiological research. The fruiting be achieved by inoculation of an autoclaved …

BE BE575588A

———— The present invention includes: 1) A process for obtaining psilocybin and psilocin, hitherto unknown compounds, endowed with psycho chotropes properties, from fungi , which method is extracted by known methods, active body cryptogamic substances of natural origin of species Psilocybe, …

CH CH377483A Hofmann Albert Sandoz Ag

Priority 1958-07-30 • Filing 1958-07-30 • Publication 1964-05-15

Claim processes for the production of the fungal genera Stro- Pharia, Conocybe, Panaeolus, Amanita, Russula or its biological variants or mutants and the following types of fungi of the genus Psilocybe: Psilocybe Semperviva Heim et Cailleux, Psilocybe caerulescens Murrill var. Mazatecorum home, …

WO EP US CN JP KR AU BR CA IL MX RU US9072747B2 Evgenia Lozinsky Peritech Pharma Ltd.

Priority 2013-03-10 • Filing 2014-03-10 • Grant 2015-07-07 • Publication 2015-07-07

A topical anorectal composition includes trimethylsiloxysilicate; at least one surfactant selected from the group consisting of sodium lauryl sulfate, alkyl- and alkoxy-dimethicone copolyol, polysorbate and a combination thereof; a non-polar volatile siloxane solvent; at least 15% (w/w) water; and …

US US20080293695A1 David William Bristol David William Bristol

Priority 2007-05-22 • Filing 2007-05-22 • Publication 2008-11-27

Drug substances comprising a pharmaceutically acceptable organic acid addition salt 6f amine containing pharmaceutically active compounds useful for the treatment of a therapeutic ailment administration and exhibiting prophylactic properties when employed in non-therapeutic administration.

WO EP US AU BR CA EA MX NO US20100292448A1 Bjorn Hagerup Nilssen Bjorn Hagerup Nilssen

Priority 2007-04-04 • Filing 2008-04-03 • Publication 2010-11-18

An extractor and a method using the extractor for extracting active principle from solid materials using an extracting fluid, said extractor comprising among others an extractor column ( 1 ), having a first side ( 22 ), a second side ( 23 ), a top side ( 24 ), and a bottom side ( 25 ); a top plate ( 10 ) for …

US US9931316B2 Paul Edward Stamets Paul Edward Stamets

Priority 2004-01-06 • Filing 2015-09-14 • Grant 2018-04-03 • Publication 2018-04-03

Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, …

WO EP US JP AU CA US8071786B2 Howard P. Sard Galenea Corp.

Priority 2004-09-27 • Filing 2009-12-14 • Grant 2011-12-06 • Publication 2011-12-06

Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

WO EP US AU CA US20040077039A1 Holtzman Holtzman

Priority 2000-09-19 • Filing 2001-09-19 • Publication 2004-04-22

Disclosed are methods for the modulation of secondary metabolite production by fungi through genetic manipulation of such fungi. Also disclosed are new commercial processes using ZBC proteins, or variants thereof, to significantly increase useful secondary metabolite production. Generally, the …

WO US US20140288454A1 Frederick Mark Paz Pulmonary Analytics

Priority 2013-03-14 • Filing 2014-03-14 • Publication 2014-09-25

The present invention provides a method for determining the presence and/or the level of drug in a subject’s system using exhaled breath of the subject.

AT AT215600B Sandoz Ag

Priority 1958-07-30 • Filing 1959-02-13 • Grant 1961-06-12 • Publication 1961-06-12

2. The method according to claim 1, characterized in that as starting material the hat mushroom Psilocybe mexicana home is used. 3. The method according to claim 1, characterized in that as starting material the hat mushroom Stropharia cubensis Earle, the hat mushroom Psilocybe Semperviva Heim et …

WO EP US CN US20130011432A1 Ronald G. Crystal Cornell University (Cctec)

Priority 2010-03-17 • Filing 2011-03-17 • Publication 2013-01-10

The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen …

US US20140220150A1 Paul Edward Stamets Paul Edward Stamets

Priority 2000-10-04 • Filing 2014-04-07 • Publication 2014-08-07

The present invention is based on a plurality of benefits from the extracts of mycelia of individual fungal species, and their mixtures, to provide an armamentarium of defenses from multiple stressors in order to help bees survive and more particularly overcome a complex of symptoms collectively …

US US8859579B2 Richard Andrew Sewell Richard Andrew Sewell

Priority 2008-03-21 • Filing 2009-03-20 • Grant 2014-10-14 • Publication 2014-10-14

Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.

WO EP US JP KR ES MX KR20090018964A 히렌 간디 테바 파마슈티컬 인더스트리즈 리미티드

Priority 2007-04-18 • Filing 2008-04-18 • Publication 2009-02-24

The present invention relates to intermediates of rosuvastatin and processes for the production thereof.

WO US US20120159656A1 David J. Gerber Galenea Corp.

Priority 2009-04-24 • Filing 2010-04-23 • Publication 2012-06-21

The present invention provides, in some aspects, methods for identifying agents useful in treating disorders or conditions associated with cognitive deficits. In some aspects, the invention provides methods for detecting a cognitive deficit in a subject.

WO EP US JP AU CA US20090318527A1 Howard Sard Howard Sard

Priority 2008-02-11 • Filing 2009-02-11 • Publication 2009-12-24

Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

WO WO2010124089A2 Michael Mulqueen Synosia Therapeutics, Inc.

Priority 2009-04-22 • Filing 2010-04-22 • Publication 2010-10-28

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with nepicastat in combination with psychosocial therapy. Also provided are methods of treating at least one phase of substance …

EP US CN JP KR KR20120128440A 김성지 삼성전자주식회사

Priority 2011-05-17 • Filing 2011-05-17 • Publication 2012-11-27

The method of claim 1, wherein the compound having the zwitterions are amino acids, bisin (bicine), tree new (tricine), sulfamic acid (sulfamic acid), alkaloids (alkaloid), psilocybin (psilocybin), CUNAULT cannabinoid (quinonoid ) and betaine (the kit is selected from the group consisting of …

US US20150056687A1 Steven Patrick Tyrrell Express Diagnostics Int’l., Inc.

Priority 2013-04-26 • Filing 2014-07-30 • Publication 2015-02-26

A lateral flow assay test device providing a structure for the lateral flow assay reactions provides for a continuous flow path of bibulous material provided in separate but contiguous regions of the device in which the bibulous layers are in fluid contact with each other thereby providing flow …

WO US US20160167042A1 Steven Patrick Tyrrell Express Diagnostics Int’l., Inc.

Priority 2013-07-30 • Filing 2014-07-30 • Publication 2016-06-16

A lateral flow assay test device providing a structure for the lateral flow assay reactions provides for a continuous flow path of bibulous material provided in separate but contiguous regions of the device in which the bibulous layers are in fluid contact with each other thereby providing flow …

WO EP US CN US20140017803A1 Robert Deans Flir Systems, Inc.

Priority 2011-03-28 • Filing 2011-03-28 • Publication 2014-01-16

Embodiments described herein provide materials, devices, and methods relating to the determination of analytes such as drugs, toxins, explosives, other controlled substances and contraband materials, and the like. In some embodiments, the analyte may be detected in vapor phase. Some embodiments …

WO EP US CN US20170281652A1 Randice Lisa Altschul Pop Test Oncology Llc

Priority 2012-07-30 • Filing 2017-06-20 • Publication 2017-10-05

This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, …

US JP JP2013233437A David J Gerber Otsuka Pharmaceut Co Ltd

Priority 2012-05-07 • Filing 2013-05-07 • Publication 2013-11-21

PROBLEM TO BE SOLVED: To provide methods for identifying and evaluating signatures in electroencephalographic oscillations that occur during onset of an exploratory activity in a subject.SOLUTION: A method includes administering a test agent to a subject who is identified as having a cognitive …

WO US WO2014064703A1 Evgenia LOZINSKY Peritech Pharma Ltd.

Priority 2012-10-28 • Filing 2013-10-27 • Publication 2014-05-01

The present invention provides liquid adhesive compositions comprising a silicone film forming agent, a volatile solvent and a pharmaceutically active agent, and methods for preparing said compositions. The invention further provides methods for treating anorectal disorders comprising …

US US8329663B2 Paul Griffin Paul Griffin

Priority 2008-01-31 • Filing 2009-01-31 • Grant 2012-12-11 • Publication 2012-12-11

The present disclosure provides compositions and methods for the treatment and elimination of chronic intracellular infections in cells or organisms. The compositions may include one or more acidic substances and one or more antimicrobial substances, administered in combination or separately. The …

WO US US20160077091A1 Steven Patrick Tyrrell Express Diagnostics International, Inc.

Priority 2013-04-26 • Filing 2014-04-25 • Publication 2016-03-17

Devices, methods, and systems are provided for testing for or detecting the presence of illegal or prohibited drugs, compounds or metabolites in non-controlled environments for testing using lateral flow drug test strips and a smart phone with digital imaging, data processing, data storage and …

WO US US20180243333A1 Eric Brown Mcmaster University

Priority 2017-02-02 • Filing 2018-02-02 • Publication 2018-08-30

Provided herein are methods and compositions for modulating a microorganism’s response to an antimicrobial agent. In one embodiment, the method comprises contacting the microorganism with an antimicrobial agent and bicarbonate. In one embodiment, provided herein are methods for treating a …

WO EP US CN JP KR AU BR CA EA IL MX US20180186797A1 Albert S. Ren Arena Pharmaceuticals, Inc.

Priority 2015-04-27 • Filing 2016-04-26 • Publication 2018-07-05

Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine …

US US20150366798A1 Evgenia Lozinsky Evgenia Lozinsky

Priority 2014-06-19 • Filing 2015-05-01 • Publication 2015-12-24

The present invention provides liquid adhesive compositions including at least one silicone resin film forming agent, at least one surfactant, at least one volatile solvent, water and at least one vasoconstrictor, where the compositions are in the form of an emulsion. The invention further …

WO WO2008122990A1 Arvind Mallinath Lali Almet Corporation Limited

Priority 2007-04-04 • Filing 2008-04-03 • Publication 2008-10-16

An extractor and a mtehod using the extractor for extracting active principle from solid materials using an extracting fluid, said extractor comprising among others an extractor column (1), having a first side (22), a second side (23), a top side (24), and a bottom side (25); a top plate (10) for …

WO EP US AU CA WO2016161138A1 Paul Edward STAMETS Stamets Paul Edward

Priority 2015-03-31 • Filing 2016-03-31 • Publication 2016-10-06

Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated, synthesized or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming …

CN CN107173054A 黄坚雄 中国热带农业科学院橡胶研究所

Priority 2017-05-27 • Filing 2017-05-27 • Publication 2017-09-19

The invention discloses a method for stropharia rugoso-annulata under a mature rubber garden. The formula comprises the following cultivation materials by dry weight ratio: 40-50% of rubber wood chips, 20-30% of gorse, 15-25% of coco coir and 5-15% of wheat bran. The method comprises the operation …

AU AU2016208412A1 Mark Moran Biotie Therapies, Inc.

Priority 2007-08-06 • Filing 2016-07-29 • Publication 2016-08-18

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in …

WO WO2009097596A1 Paul Griffin Paul Griffin

Priority 2008-01-31 • Filing 2009-01-31 • Publication 2009-08-06

The present disclosure provides compositions and methods for the treatment and elimination of chronic intracellular infections in cells or organisms. The compositions may include one or more acidic substances and one or more antimicrobial substances, administered in combination or separately. The …

WO WO2019079742A1 Shlomi RAZ Eleusis Benefit Corporation, Pbc

Priority 2017-10-19 • Filing 2018-10-19 • Publication 2019-04-25

The present invention provides methods and systems of enhancing the safety of psychedelic drug therapies (e.g., 5-HT2A agonists (e.g., LSD and psilocybin), dissociatives, and empathogens), for example, as part of a complex therapy. In particular, the invention features methods and systems for …

WO EP US CN JP KR AU BR CA EA MX EP3328835A1 Juerg Lehmann Arena Pharmaceuticals, Inc.

Priority 2015-07-31 • Filing 2016-07-28 • Publication 2018-06-06

Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, …

CN CN108619214A 王慎君 王慎君

Priority 2017-03-15 • Filing 2017-03-15 • Publication 2018-10-09

A medicament for treating tumors, characterized in that technical, tobacco acid content mood and boost the confidence of IOOOmg / bag, psilocybin 30mg / bag, Rhodiola extract 500mg / package; purifying the blood lipoic acid content of 350mg / package, propolis content IOOOmg / bag, pangamic acid I …

WO AU CA AU2017313908A1 Michelle Kasem Arena Pharmaceuticals, Inc.

Priority 2016-08-19 • Filing 2017-08-18 • Publication 2019-02-28

The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT

AU AU2014202047A1 Mark Moran Biotie Therapies, Inc.

Priority 2007-08-06 • Filing 2014-04-11 • Publication 2014-05-01

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in …

WO WO2019026019A1 Ezekiel Golan Therapeutic Adjuncts Inc.

Priority 2017-08-03 • Filing 2018-08-02 • Publication 2019-02-07

The present invention relates to methods of drug-assisted psychotherapy with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising 3-MMC for use in the treatment of subjects undergoing psychotherapeutic intervention. In …

DD DD265636A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1987-10-30 • Filing 1987-10-30 • Publication 1989-03-08

The invention relates to the microbial production of indole derivatives. It is applicable for the production of model substances for neurobiological and psychiatric examinations. The invention consists in the use of culture media, which consist of complex natural or synthetic substrates, each of …

WO WO2019081764A1 Ana María PEREZ CASTILLO Consejo Superior De Investigaciones Científicas (Csic)

Priority 2017-10-26 • Filing 2018-10-26 • Publication 2019-05-02

The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor …

WO EP CN CA CN107073293A E·洛金斯基 托匹泰克以色列制药有限公司

Priority 2015-05-01 • Filing 2015-05-01 • Publication 2017-08-18

A topical composition includes at least one film forming agent; at least one surfactant; at least one non-polar volatile siloxane solvent; and a therapeutically effective concentration of at least one pharmaceutical agent selected from the groups comprising vasoconstrictors and antifibrinolytics, …

DD DD266811A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1987-11-09 • Filing 1987-11-09 • Publication 1989-04-12

… recovery of indoles from fungal mycelia, wherein using cheap “natural raw materials cultivation under sterile conditions and at variable temperatures is effected, wherein the zusätzllcho Verfahrenaschritt the previous separation of the mycelia is omitted and largely constant yields of psilocybin to …

DD DD273449A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1988-06-29 • Filing 1988-06-29 • Publication 1989-11-15

The invention relates to the microbial production of 4-substituted indole compounds. It is applicable to the extraction of active ingredients for the experimental neurobiology. The invention consists in the use of solid media, which consist of mixtures of complex natural substrates, each of which …

WO WO2018195455A1 Suzanne RUSS Eleusis Benefit Corporation, Pbc

Priority 2017-04-20 • Filing 2018-04-20 • Publication 2018-10-25

The invention features methods of identifying a subject as being likely to have a positive therapeutic response to a psychedelic agent. Methods of the invention also include administering a psychedelic agent to a subject (e.g., a subject that has been identified as likely to respond positively …

WO EP US ES US8168785B2 Thomas R. Malefyt Biotie Therapies, Inc.

Priority 2009-06-17 • Filing 2009-06-17 • Grant 2012-05-01 • Publication 2012-05-01

Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at …

WO EP US JP AR AU DE DK ES FR PT TW ZA JP2000504681A インペラート，アスンタ ローン―プーラン・ロレ・ソシエテ・アノニム

Priority 1996-02-07 • Filing 1997-02-03 • Publication 2000-04-18

(57) Abstract: Pyrrolidine derivatives having general formula (I), their racemates if they contain one or more asymmetric centers and enantiomers, and their salts, other than alcohol abuse , use for the manufacture of a medicament intended for the treatment of abuse of substances causing drug or …

DD DD278600A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1988-12-23 • Filing 1988-12-23 • Publication 1990-05-09

The invention relates to the microbial production of tryptophan derivatives. It is applicable to the extraction of active ingredients for the experimental neurobiology and drug synthesis. The invention consists in the use of solid media consisting of substrates, may be added to the …

CN107771613A 胡惠萍 广东省微生物研究所

Priority 2017-10-25 • Filing 2017-10-25 • Publication 2018-03-09

The invention relates to a novel strain and an artificial cultivation method thereof and in particular relates to a novel Gymnopilus luteofolius strain as well as a cultivation method and applicationof the novel Gymnopilus luteofolius strain. The novel Gymnopilus luteofolius strain is Gymnopilus …

DD DD287053A5 Jochen Gartz Akademie Der Wissenschaften Der Ddr,De

Priority 1989-08-15 • Filing 1989-08-15 • Publication 1991-02-14

The invention relates to a process for the recovery of the active ingredient baeocystin by biotransformation of tryptamine means of basidiospores higher fungi. The substance can be applied as a pharmaceutical agent and as a model substance in the neurochemical basic research. After the inoculation …

DD DD255749A1 Jochen Gartz Akad Wissenschaften Ddr

Priority 1986-11-06 • Filing 1986-11-06 • Publication 1988-04-13

The invention relates to the microbial production of indole alkaloids. It is applicable for the preparation of model compounds for the experimental psychiatric research and for neurobiological studies. The invention consists in the use of a new nutrient medium, which is composed of synthetic and …

WO EP US CN JP KR AU BR CA MX NZ RU ZA EP1605973B1 Martin F. Bachmann Cytos Biotechnology AG

Priority 2003-03-26 • Filing 2004-03-25 • Grant 2012-09-26 • Publication 2012-09-26

(g) methylenedioxymethamphetamine; (h) methamphetamine; (i) methylphenidate; (j) nicotine; (k) LSD; (l) mescaline; (m) psilocybin; and (n) tetrahydrocannabinol. The composition of any one of claims 1 to 6, wherein said antigen is derived from the group consisting of: (a) viruses; (b) bacteria; (c) …

WO EP US JP AT AU CA DE DK JP4965625B2 ゴールドスミス，ニール エボルバ アクチェンゲゼルシャフト

Priority 2001-01-25 • Filing 2009-10-07 • Grant 2012-07-04 • Publication 2012-07-04

A library comprising a collection of individual cells, Each cell The following formula: (here, rs SP represents a spacer of at least two bases, X represents an expressible nucleotide sequence, PR denotes a promoter capable of controlling the expression of X in the cell, TR represents a terminator, …

WO US CN AU CA CL MA CN105792942B J·B·海因斯 佐治亚-太平洋化工品有限公司

Priority 2013-10-09 • Filing 2014-10-08 • Grant 2019-04-16 • Publication 2019-04-16

There is provided collector composition and its preparation and applied to the method for purifying one or more raw materials.Collector composition may include one or more amido amines with Formula I and the amine with Formula I V, and wherein amido amine and the weight ratio of amine can be about …

EP JP AU CA DK ES ZA CA1246446A Rene Muntwyler Rene Muntwyler

Priority 1984-02-15 • Filing 1985-02-13 • Grant 1988-12-13 • Publication 1988-12-13

Abstract Process for the manufacture of pharmaceutical compositions containing unilamellar liposomes The present invention relates to a process for the maunfacture of pharmaceutical compositions in the form of aqueous dispersions containing unilammellar liposomes comprising (I) an amphiphatic …

US US9421266B2 Clifford Riley King Pisgah Laboratories, Inc.

Priority 2007-05-22 • Filing 2012-12-21 • Grant 2016-08-23 • Publication 2016-08-23

Drug substances comprising a amine containing pharmaceutically active compound, and at least one of an alditol acetal and an aromatic organic acid as an addition salt or an additive.

US US10254298B1 Chung-Yan Koh National Technology & Engineering Solutions Of Sandia, Llc

Priority 2015-03-25 • Filing 2015-12-02 • Grant 2019-04-09 • Publication 2019-04-09

The various technologies presented herein relate to identifying whether an individual has taken, and/or is under the influence of, a restricted drug. A density separation technique is utilized, wherein a sample (e.g., blood, saliva, urine, etc.,) which may include an analyte is exposed to a first …

US US9759733B1 Michael D. Callahan Michael D. Callahan

Priority 2016-04-08 • Filing 2016-04-08 • Grant 2017-09-12 • Publication 2017-09-12

A highly portable, paper and swab-based detection kit is provided for identifying Amphetamine, Cannabis, Cocaine, Heroin, selected synthetic Cannabinoid, and amphetamine based Cathinone type stimulants, and cannabis consumable products. A method of mass manufacture providing low cost kits with …

WO EP US CN JP AT AU BR CA HK IL MX NZ RU ZA EP1532167B1 Martin F. Bachmann Cytos Biotechnology AG

Priority 2002-07-17 • Filing 2003-07-14 • Grant 2012-01-25 • Publication 2012-01-25

The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for …

WO EP US JP AT AU CA DE JP4472345B2 アレキサンドラ・エミ・ペ・サンタナ・ソエレンセン エヴォルヴァ・リミテッドＥｖｏｌｖａ Ｌｔｄ．

Priority 2002-01-25 • Filing 2003-01-24 • Grant 2010-06-02 • Publication 2010-06-02

A method for evolving a cell producing at least one compound having two or more predetermined functionalities, the method comprising the steps of: a) at least one of each has said heterologous sequence of at least two heterologous expressible nucleotide sequences provides a cell composition …